Allergy-specific benefit verification goes well beyond confirming general outpatient coverage. We establish whether skin testing is covered and at what payer-specific unit cap, whether subcutaneous immunotherapy is covered and whether the plan imposes a serum preparation dose cap on 95165, and what the plan's coverage policy is for the specific biologic under consideration, Xolair, Dupixent, Nucala, Fasenra, or Tezspire, including whether it falls under the medical benefit as a physician-administered drug or under the pharmacy benefit requiring specialty pharmacy dispensing. We confirm the step therapy requirements and biomarker documentation standards the prior authorization must satisfy before any drug is administered. A PA failure discovered after a biologic has already been administered and billed is one of the highest-dollar denial scenarios in allergy practice, because biologic unit costs make a single uncovered administration financially material, and our comprehensive biologic PA management reviews biomarker documentation before every submission to prevent exactly that outcome.

The per-test billing framework is the foundational revenue variable in allergy testing, and it is the piece most billing teams outside the specialty misapply. CPT 95004, 95024, 95028, and 95044 all bill per individual allergen applied, not per testing session, panel, or tray, so a 40-allergen prick test panel correctly generates 40 units of 95004, and any billing team applying one or two codes for the entire encounter underrecovers per-test revenue every time. Medicare limits how many percutaneous tests are reimbursable per date of service, and commercial payers vary in the number of tests they recognize per visit from limited to unlimited depending on the specific plan and local coverage determination. The number of units billed must match the number of allergens documented in the nursing allergy testing record, allergen names, testing method, and reaction, since that documentation is exactly what supports per-test unit billing on audit. We verify the allergen count against the testing record before every skin testing claim goes out.

Subcutaneous allergen immunotherapy is a two-component billing event, and practices billing only one component systematically underrecover SCIT revenue. Serum preparation, CPT 95165 per dose, is billed when a patient's individualized allergen extract is mixed and prepared, with documentation requirements covering allergen names, source lot numbers, concentrations, dose count, and preparation date. Injection administration, 95115 for a single injection or 95117 for two or more injections in one visit, is billed on each injection visit date for the professional service of delivering the extract subcutaneously and observing the patient for the required post-injection period. Medicare and commercial payers cap the number of doses billable under 95165 per course of immunotherapy, and exceeding the cap without clinical justification generates denials that are difficult to appeal. Build-up and maintenance phases use the same administration codes, but concentration and dose must be documented at each visit to confirm appropriate progression, and our SCIT workflow tracks both components and every patient's serum cap status continuously.

Biologic drug administration is the highest-value revenue component in many allergy and immunology practices, and it is the most vulnerable to per-unit billing errors. Each biologic uses a specific HCPCS J-code that bills in the exact per-milligram units its descriptor defines: J2357 for omalizumab (Xolair) per 0.5 mg, J0222 for dupilumab (Dupixent) per 1 mg, J2182 for mepolizumab (Nucala) per 1 mg, and J0517 for benralizumab (Fasenra) per 10 mg. Billing the number of vials rather than the calculated milligram-based unit count is a systematic error; a 300 mg dose of dupilumab requires 300 units of J0222, and billing 1 unit for one vial dramatically underrecovers drug reimbursement. Subcutaneous biologic administration bills with CPT 96372 alongside the drug HCPCS code, and every claim requires NDC reporting plus prior authorization documentation, biomarker results, prior controller medication failure history, and indication-specific clinical criteria, that must stay current at every administration, not just at treatment initiation. We verify biologic drug codes and unit calculations before every drug claim is submitted.

Venom immunotherapy uses a completely separate billing framework from inhalant allergen immunotherapy, for both testing and serum preparation. Venom skin testing uses 95017 per venom tested and 95018 where applicable, and venom serum preparation (95145 through 95149) bills per dose prepared by the number of insect venoms mixed, from single venom under 95145 up to five or more under 95149. Venom injection administration (95130 through 95134) bills per visit by the number of venoms administered in that visit. Coverage requires documentation of a systemic allergic reaction history, anaphylaxis, generalized urticaria, or cardiovascular collapse, not just local swelling, together with a positive venom-specific skin test or specific IgE result, and billing venom immunotherapy for patients with only local reactions creates a medical necessity compliance issue at most payers. We confirm coverage eligibility before billing every venom immunotherapy claim.

Patch testing for allergic contact dermatitis is a multi-visit billing scenario that generates revenue across three separate encounters when managed correctly. Day 1 involves placing allergen patches, billed under 95044 per allergen applied. Day 2 or 3 is the initial reading, where the allergist interprets each patch reaction and grades the response as positive, negative, irritant, or doubtful, generating a professional service code for that interpretation work. Day 4 or 5 is the final reading, a third separately billable encounter. Practices that bill only the placement day and treat the reading visits as routine check-ins forfeit the professional interpretation revenue from two additional encounters per patch testing course, and each reading's documentation must record the specific patch names and reaction grades to support billing. We manage the full multi-visit patch testing billing workflow so every reading encounter is captured.

Each allergy denial category requires its own appeal approach. Skin testing medical necessity denials require the testing record documenting the specific allergens tested, the clinical rationale for testing them, and the patient's symptom history. Serum preparation denials for exceeding a cap require the mixing records confirming the claimed doses correspond to actual preparation events on documented dates. Biologic prior authorization denials require the biomarker documentation, prior controller therapy failure history, and the clinical criteria citation from the payer's specific biologic coverage policy. Modifier 25 E/M denials require the clinical note demonstrating that the documented work addressed conditions distinct from the pre-procedure assessment. Venom immunotherapy denials on medical necessity grounds require the systemic reaction history and the positive venom test result. Our allergy-specific appeals team builds each appeal to the exact standard the denial category requires.

Allergy AR includes per-test testing claims, per-dose SCIT billing, per-visit injection administration, and high-value biologic drug claims where individual administrations can be worth thousands of dollars at Medicare ASP-based reimbursement. We monitor serum preparation cap utilization by patient to flag when the remaining cap will be exhausted, track biologic administration claims separately from service claims given their per-administration value, and follow up on E/M-with-modifier-25 denials before timely filing windows close. Monthly analytics cover revenue by service category, skin testing versus SCIT administration versus serum preparation versus biologic drug versus E/M versus venom immunotherapy, biologic drug revenue versus service revenue, per-test revenue trends, serum preparation dose utilization against plan caps, biologic PA approval rates by drug and payer, and denial trends by reason code and service category, all delivered through a dedicated allergy account manager.